The FDA’s problem isn’t personnel — it’s enforcement

President Donald Trump’s FDA chief is out, but the reason behind it is not what many think. We must be careful not to learn the wrong lessons from Marty Makary’s resignation.

The narrative around the resignation of former Food and Drug Administration official Makary, as reported in the media, implies he was pushed out for refusing to approve fruit-flavored vapes. In reality, the FDA reversed its strict stance against the product last week, and Makary’s departure involved several unrelated factors that marked his tenure, including mass layoffs and policy disputes with lawmakers and Trump. The media’s increased focus on political speculation is irresponsible. It distracts from the real issue at hand: the agency’s failure to implement regulations on the flavored vapes already on the market.

The reversal doesn’t guarantee the safety of products for sale in gas stations, since many were already available before approval. Instead, it shows the FDA’s inconsistent regulatory